Literature DB >> 12032333

A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.

Ajeeta B Dash1, Ifor R Williams, Jeffery L Kutok, Michael H Tomasson, Ema Anastasiadou, Kathleen Lindahl, Shaoguang Li, Richard A Van Etten, Julian Borrow, David Housman, Brian Druker, D Gary Gilliland.   

Abstract

Constitutive activation of tyrosine kinases, such as the BCR/ABL fusion associated with t(9;22)(q34;q22), is a hallmark of chronic myeloid leukemia (CML) syndromes in humans. Expression of BCR/ABL is both necessary and sufficient to cause a chronic myeloproliferative syndrome in murine bone marrow transplantation models, and absolutely depends on kinase activity. Progression of CML to acute leukemia (blast crisis) in humans has been associated with acquisition of secondary chromosomal translocations, including the t(7;11)(p15;p15) resulting in the NUP98/HOXA9 fusion protein. We demonstrate that BCR/ABL cooperates with NUP98/HOXA9 to cause blast crisis in a murine model. The phenotype depends both on expression of BCR/ABL and NUP98/HOXA9, but tumors retain sensitivity to the ABL inhibitor STI571 in vitro and in vivo. This paradigm is applicable to other constitutively activated tyrosine kinases such as TEL/PDGFbetaR. These experiments document cooperative effects between constitutively activated tyrosine kinases, which confer proliferative and survival properties to hematopoietic cells, with mutations that impair differentiation, such as the NUP98/HOXA9, giving rise to the acute myeloid leukemia (AML) phenotype. Furthermore, these data indicate that despite acquisition of additional mutations, CML blast crisis cells retain their dependence on BCR/ABL for proliferation and survival.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12032333      PMCID: PMC124303          DOI: 10.1073/pnas.102583199

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines.

Authors:  S Yokota; H Kiyoi; M Nakao; T Iwai; S Misawa; T Okuda; Y Sonoda; T Abe; K Kahsima; Y Matsuo; T Naoe
Journal:  Leukemia       Date:  1997-10       Impact factor: 11.528

2.  Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b.

Authors:  E Kroon; J Krosl; U Thorsteinsdottir; S Baban; A M Buchberg; G Sauvageau
Journal:  EMBO J       Date:  1998-07-01       Impact factor: 11.598

3.  Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice.

Authors:  L Z He; C Tribioli; R Rivi; D Peruzzi; P G Pelicci; V Soares; G Cattoretti; P P Pandolfi
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

4.  The t(11;16)(q23;p13) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene.

Authors:  T Taki; M Sako; M Tsuchida; Y Hayashi
Journal:  Blood       Date:  1997-06-01       Impact factor: 22.113

5.  CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins.

Authors:  M Carroll; S Ohno-Jones; S Tamura; E Buchdunger; J Zimmermann; N B Lydon; D G Gilliland; B J Druker
Journal:  Blood       Date:  1997-12-15       Impact factor: 22.113

6.  Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

Authors:  C Gambacorti-Passerini; P le Coutre; L Mologni; M Fanelli; C Bertazzoli; E Marchesi; M Di Nicola; A Biondi; G M Corneo; D Belotti; E Pogliani; N B Lydon
Journal:  Blood Cells Mol Dis       Date:  1997-12       Impact factor: 3.039

7.  Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences.

Authors:  J L Grisolano; R L Wesselschmidt; P G Pelicci; T J Ley
Journal:  Blood       Date:  1997-01-15       Impact factor: 22.113

8.  Cloning of ELL, a gene that fuses to MLL in a t(11;19)(q23;p13.1) in acute myeloid leukemia.

Authors:  M J Thirman; D A Levitan; H Kobayashi; M C Simon; J D Rowley
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

9.  A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.

Authors:  V Lacronique; A Boureux; V D Valle; H Poirel; C T Quang; M Mauchauffé; C Berthou; M Lessard; R Berger; J Ghysdael; O A Bernard
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

10.  The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9.

Authors:  J Borrow; A M Shearman; V P Stanton; R Becher; T Collins; A J Williams; I Dubé; F Katz; Y L Kwong; C Morris; K Ohyashiki; K Toyama; J Rowley; D E Housman
Journal:  Nat Genet       Date:  1996-02       Impact factor: 38.330

View more
  75 in total

1.  Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia.

Authors:  Benjamin J Frisch; John M Ashton; Lianping Xing; Michael W Becker; Craig T Jordan; Laura M Calvi
Journal:  Blood       Date:  2011-09-28       Impact factor: 22.113

2.  β-Arrestin2 mediates the initiation and progression of myeloid leukemia.

Authors:  Mark Fereshteh; Takahiro Ito; Jeffrey J Kovacs; Chen Zhao; Hyog Young Kwon; Valerie Tornini; Takaaki Konuma; Minyong Chen; Robert J Lefkowitz; Tannishtha Reya
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-05       Impact factor: 11.205

Review 3.  NUP98 fusion in human leukemia: dysregulation of the nuclear pore and homeodomain proteins.

Authors:  Takuro Nakamura
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

4.  Imaging hematopoietic precursor division in real time.

Authors:  Mingfu Wu; Hyog Young Kwon; Frederique Rattis; Jordan Blum; Chen Zhao; Rina Ashkenazi; Trachette L Jackson; Nicholas Gaiano; Tim Oliver; Tannishtha Reya
Journal:  Cell Stem Cell       Date:  2007-11       Impact factor: 24.633

5.  BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress.

Authors:  M Koptyra; K Cramer; A Slupianek; C Richardson; T Skorski
Journal:  Leukemia       Date:  2008-04-10       Impact factor: 11.528

6.  RNA binding protein MSI2 positively regulates FLT3 expression in myeloid leukemia.

Authors:  Ayuna Hattori; Daniel McSkimming; Natarajan Kannan; Takahiro Ito
Journal:  Leuk Res       Date:  2017-01-11       Impact factor: 3.156

7.  Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells.

Authors:  Manabu Kurokawa; Takahiro Ito; Chih-Sheng Yang; Chen Zhao; Andrew N Macintyre; David A Rizzieri; Jeffrey C Rathmell; Michael W Deininger; Tannishtha Reya; Sally Kornbluth
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-16       Impact factor: 11.205

Review 8.  Right on target: eradicating leukemic stem cells.

Authors:  Daniela S Krause; Richard A Van Etten
Journal:  Trends Mol Med       Date:  2007-11-05       Impact factor: 11.951

9.  NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia.

Authors:  Ying-Wei Lin; Christopher Slape; Zhenhua Zhang; Peter D Aplan
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

Review 10.  Molecular biology of bcr-abl1-positive chronic myeloid leukemia.

Authors:  Alfonso Quintás-Cardama; Jorge Cortes
Journal:  Blood       Date:  2008-09-30       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.